Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and hyoscine butylbromide, an antispasmodic agent.
## Primary Indications
* Symptomatic relief of abdominal pain and cramping associated with irritable bowel syndrome (IBS) and other gastrointestinal disorders.
* Management of dysmenorrhea.
## Adult Dosing
* **General:** 1 tablet (mefenamic acid 250 mg / hyoscine butylbromide 10 mg) three times daily.
* **Maximum:** Not to exceed 4 tablets daily.
## Pediatric Dosing
* **Children 12 years and older:** 1 tablet three times daily.
* **Children under 12 years:** Safety and efficacy not established. Consult local pediatric guidelines or specialist.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Mefenamic acid is renally excreted.
* **Hepatic Impairment:** Use with caution. Mefenamic acid is hepatically metabolized.
## Contraindications
* Known hypersensitivity to mefenamic acid, hyoscine butylbromide, or any component of the formulation.
* Active gastrointestinal bleeding or perforation.
* Glaucoma (especially narrow-angle glaucoma).
* Myasthenia gravis.
* Prostatic hypertrophy with urinary retention.
* Tachyarrhythmias.
* Ileus or toxic megacolon.
* Severe renal or hepatic impairment.
## Adverse Effects
* **Common (Mefenamic Acid):** Gastrointestinal upset (nausea, vomiting, diarrhea, constipation, abdominal pain), headache, dizziness, rash.
* **Common (Hyoscine Butylbromide):** Dry mouth, blurred vision, constipation, urinary retention, tachycardia.
* **Serious:** Gastrointestinal bleeding, ulceration, perforation, cardiovascular thrombotic events (NSAID class effect), anaphylaxis, severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis).
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Other NSAIDs and Aspirin:** Increased risk of gastrointestinal adverse effects and reduced efficacy of aspirin's cardioprotective effect.
* **Corticosteroids:** Increased risk of gastrointestinal ulceration and bleeding.
* **Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs):** Increased risk of gastrointestinal bleeding.
* **Diuretics and Antihypertensives:** May reduce their efficacy and increase risk of renal impairment.
* **Anticholinergic agents:** Additive anticholinergic effects.
* **Metoclopramide:** May antagonize the effects of hyoscine butylbromide.
## Monitoring
* Monitor for signs and symptoms of gastrointestinal bleeding or perforation.
* Assess for renal and hepatic function, particularly in patients with pre-existing impairment or those on long-term therapy.
* Evaluate for signs of adverse effects related to both mefenamic acid and hyoscine butylbromide.
## Clinical Pearls
* This combination should be used for symptomatic relief and not as a long-term management strategy for chronic conditions without further evaluation.
* Administer with food or milk to minimize gastrointestinal upset.
* Due to anticholinergic effects, caution is advised in the elderly and in patients with conditions exacerbated by anticholinergics.
* Discontinue if significant adverse effects occur or if symptoms do not improve within a reasonable timeframe.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and product monographs for complete details. Dosing and indications may vary based on local guidelines and individual patient factors.
